创新药板块走低 科伦博泰生物(06990)跌7.67% 当前板块仍处估值修复行情

金吾财讯
Jul 08

金吾财讯 | 创新药板块走低,药明生物(02269)跌1.79%,亚盛医药(06855)跌1.93%,康方生物(09926)跌1.95%,云顶新耀(01952)跌2.12%,三生制药(01530)跌2.41%,药明合联(02268)跌2.81%,药明康德(02359)跌2.99%,歌礼制药-B(01672)跌4.08%,欧康维视生物-B(01477)跌4.62%,博安生物(06955)跌5.98%,科伦博泰生物(06990)跌7.67%。消息面上,创新药板块迎来多重驱动因素,政策、产业出海、资金调仓共同推动板块估值修复。政策层面,7月3日CGT药品审评征求意见稿将临床试验审评周期由60个工作日压缩至30日,补充申请时限由200个工作日缩短至130个工作日,搭配创新药豁免集采、医保初审通过率92%同比提升8个百分点等政策,形成产业宽松监管环境。产业端出海授权数据亮眼,2026上半年中国创新药BD交易总额976.25亿美元同比增40%,首付款62.8亿美元同比提升124%,石药百利天恒大额跨境授权落地,多家药企确认授权收入并逐步实现扭亏。资金端,高位AI半导体板块资金流出,公募一季度创新药持仓占比升至9.53%,年内166家生物医药企业累计回购133.45亿元。有研究指,创新药板块年内曾两轮短期反弹,本轮行情依托政策组合、高含金量海外交易、机构持续加仓三大不同支撑,但机构表示当前仅为估值修复行情,基本面全面反转仍需中期、三季度财报验证,后续走势重点跟踪企业盈利兑现与CGT正式政策落地进度。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10